Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

AGN

Algernon Pharmaceuticals (AGN)

Algernon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:AGN
DateTimeSourceHeadlineSymbolCompany
02/11/20218:00AMInvestorsHub NewsWireAlgernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study ProtocolCSE:AGNAlgernon Pharmaceuticals Inc
06/04/202012:41PMInvestorsHub NewsWireAlgernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19CSE:AGNAlgernon Pharmaceuticals Inc
04/13/20209:44AMInvestorsHub NewsWireAlgernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) HowardCSE:AGNAlgernon Pharmaceuticals Inc
03/13/20208:40AMInvestorsHub NewsWireAlgernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and EmergencyCSE:AGNAlgernon Pharmaceuticals Inc
03/06/20208:32AMInvestorsHub NewsWireAlgernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for CoronavirusCSE:AGNAlgernon Pharmaceuticals Inc
07/31/20197:22AMInvestorsHub NewsWireAlgernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...CSE:AGNAlgernon Pharmaceuticals Inc
07/29/20198:32AMInvestorsHub NewsWireAlgernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...CSE:AGNAlgernon Pharmaceuticals Inc
07/03/20199:06AMInvestorsHub NewsWireAlgernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%CSE:AGNAlgernon Pharmaceuticals Inc
06/04/20198:00AMInvestorsHub NewsWireQ&A with Christopher J. Moreau CEO of Algernon PharmaceuticalsCSE:AGNAlgernon Pharmaceuticals Inc
05/28/20198:00AMInvestorsHub NewsWireAlgernon Pharmaceuticals: Join us for an interview with the CEO and CSOCSE:AGNAlgernon Pharmaceuticals Inc
05/23/20198:04AMInvestorsHub NewsWireRepurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBDCSE:AGNAlgernon Pharmaceuticals Inc
 Showing the most relevant articles for your search:CSE:AGN